Neuro-Oncology Practice
|
|
- Lynette Conley
- 5 years ago
- Views:
Transcription
1 Neuro-Oncology Practice Neuro-Oncology Practice 3(2), 71 76, 2016 doi: /nop/npv043 Advance Access date 16 October 2015 Anaplastic astrocytoma and non-1p/19q co-deleted anaplastic oligoastrocytoma: long-term survival, employment, and performance status of survivors Elena I. Pentsova, Anne S. Reiner, Katherine S. Panageas, and Lisa M. DeAngelis Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (E.I.P., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY (A.S.R., K.S.P.) Corresponding Author: Elena I. Pentsova, MD, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York Background. Despite optimal treatment for patients with anaplastic gliomas, median survival is 2 to 5 years, but some young adults survive longer. We sought to evaluate the functional and employment status of long-term survivors (5 years or more) diagnosed with anaplastic astrocytoma or non-1p/19q co-deleted anaplastic oligoastrocytoma. Methods. We retrospectively identified patients with a diagnosis of anaplastic glioma at Memorial Sloan Kettering Cancer Center from 1999 to We reviewed demographics, pathology, 1p/19q status, survival, and treatment. Overall survival was estimated by the Kaplan-Meier method. Results. There were 195 patients; 167 with anaplastic astrocytoma and 28 with anaplastic oligoastrocytoma. All patients were observed either to death or last follow-up. Sixty-four patients (33%) were identified as long-term survivors; 58% of these were men. The median age of the long-term survivors was 39 years and the median Karnofsky Performance Score was 100 at diagnosis. Thirteen patients underwent stereotactic biopsy, 7 had a gross total resection, and 44 a subtotal resection. Fifty-four patients completed radiation therapy as initial treatment; 54 received chemotherapy. Five years following diagnosis, median KPS was 90 and 55% of longterm survivors were employed and remained fully functional. Conclusions. One-third of patients with non-co-deleted anaplastic glioma were long-term survivors, and more than one-half of longterm survivors resumed their prior level of employment and activity. However, a significant proportion could not return to normal function. These findings have serious implications for the social and financial status of these predominantly young adult survivors. Keywords: Anaplastic astrocytoma, anaplastic oligoastrocytoma, employment. Anaplastic glioma (AG) has an annual incidence of approximately 5 per people and accounts for only 6.8% of all primary brain tumors. 1 These aggressive gliomas often affect young adults in the prime of life causing significant disability as well as death. Despite optimal therapy, long-term survival of 5 or more years is inversely related to age and has been reported in 48% of patients age 20 to 44 years, 29% of those age 45 to 54 years, and 9% of those age 55 to 64 years. 2,3 The standard treatment for AG remains controversial, but typically includes radiotherapy and chemotherapy, 4,5 similar to treatment for glioblastoma. 6 8 Long-term survivors of malignant glioma, particularly glioblastoma, usually have significant cognitive impairment and neurological deficits attributed to the disease and treatment. 9,10 The functional and employment status of the adult AG survivor is unknown, but is more important given the greater potential for long-term survival. We sought to identify long-term survivors of an AG to assess the late consequences, performance status, and employment status of these survivors. Patients and Methods We retrospectively identified patients 18 years or older who were diagnosed with AG at Memorial Sloan Kettering Cancer Center (MSKCC) between January 1, 1999 and November 31, This study was approved by the MSKCC Institutional Review Board. All patients were identified through the institutional and Department of Neurology databases available at our institution. We included patients with histologically confirmed anaplastic astrocytoma (AA) and those with anaplastic oligoastrocytomas (AOA) who had 1p/19q intact, 1p intact and 19p not tested, and AOA with unknown 1p/19q status. Patients with AOA known to be 1p/19q co-deleted and anaplastic oligodendrogliomas Received 12 May 2015, Advance Access publication 16 October 2015 # The Author(s) Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please journals.permissions@oup.com. 71
2 were excluded. Patients with pre-existing low-grade gliomas were included only if anaplastic transformation was confirmed by histological diagnosis; the date of pathologic demonstration of anaplasia was considered the date of AG diagnosis. Pathology for all cases was reviewed at MSKCC. Initial treatment of eligible patients included surgery, radiation therapy with or without chemotherapy, or chemotherapy alone. Follow-up extended through August 31, Statistics Overall survival was calculated from date of AG diagnosis until date of death or last follow-up. Survival was estimated by the Kaplan-Meier method and comparisons between groups were made using the log-rank test. To investigate the association between variables of interest and employment status at 5 years, logistic regression models were used in which being employed at 5 years was the outcome, with adjustment for baseline employment status. Variables of interest were separately modeled and included sex, age at diagnosis, histology, Karnofsky Performance Score (KPS), and tumor location. Analyses were done in SAS version 9.2 (Cary, NC). Study Design For the purpose of this study, long-term survivors were defined as those with AG who lived more than 5 years from the time of tissue diagnosis. As per inclusion criteria, all patients were evaluated in our institution and had follow-up either by clinic visits or through a medical-record review for 5 years or more. We sought to assess their performance and employment status 5 years+6 months from diagnosis. Employment data were collected from chart reviews and by interviewing the patients primary neurooncologists. Data on cognitive status were collected from patient s/caregiver s reports at the visit, from neurologic examinations, and from Mini-Mental State Examinations if performed; we also used any available neurocognitive evaluations although these were rare. If a patient had hemiparesis that significantly affected his or her mobility, was wheelchair bound and unable to perform activities of daily living, was significantly aphasic, had a prominent visual deficit, or had severe gait abnormalities, then the patient was considered to have a severe neurologic deficit. Patients with poor memory, poor judgment, and requiring significant assistance to write checks or shop, or patients with frequent, uncontrolled seizures on multiple antiepileptic medications reporting difficulty with memory and concentration were considered to have severe cognitive impairment. If a patient was a full-time homemaker when AG was diagnosed and returned to that activity, it was considered equivalent to returning to full-time employment. If a patient was retired at the time of AG diagnosis and developed neurologic or cognitive impairment, it was considered equivalent to being unemployed. For a patient who was unable to return to work after diagnosis or went on disability, his or her employment status changed to disability. Results Patient Characteristics A total of 207 patients with an AG were seen at MSKCC in this time interval. Twelve patients were seen as a second opinion only and were excluded from our analysis. The remaining 195 patients were observed either to their death or last follow-up (Table 1). One hundred eleven patients (57%) were men. Median age at diagnosis was 42 years (range, years); 167 patients (86%) were diagnosed with AA, and 28 (14%) with AOA, 14 of whom had an unknown 1p/19q status. Pre-existing low-grade glioma was present in 28 patients (14%). The frontal lobe was invaded by tumor in 91 patients (47%). At diagnosis the median KPS was 90 (range, ). Subtotal resection was performed in 124 patients (64%), gross total resection in 10 (5%), and biopsy only in 61 (31%). One hundred sixty-three patients (84%) received radiation therapy and 151 (77%) received chemotherapy as initial treatment. Higher KPS (P,.0001), younger age at diagnosis (P ¼.0005) and extent of surgical resection (P,.0001) were prognostic factors in predicting longer survival. Median overall survival of the entire cohort was 2.5 years (95% CI, ) from AG diagnosis and median follow-up for survivors was 7.8 years (Fig. 1). At the last follow-up, 153 patients were dead and 42 were alive. Long-term Survivors Sixty-four patients (33%) were long-term survivors. Median age at diagnosis was 39 years (range, years); 5% of patients were 65 years or older. Thirty-seven (58%) patients were men. Fifty-two (81%) were diagnosed with an AA, and 12 (19%) had AOA; 4 of the AOAs had intact 1p/19q, 1 had intact 1p, and 1p/19q was not tested in 7. Pre-existing low-grade glioma was seen in 9 patients (14%). At diagnosis, median KPS was 100. After adjusting for employment at baseline, those with higher KPS (P ¼.04) at diagnosis and women (P ¼.01) were more likely to be employed at 5 years. The variables of age at diagnosis, histology (AOA vs AA), or tumor location (frontal vs other) were not associated with statistically significant differences in employment status among long-term survivors. Median survival of the long-term survivors was 9.7 years (95% CI, 7.5-no upper limit) from diagnosis. Thirty-seven patients (58%) had tumor progression; in 23 patients tumor recurred within 5 years. At last follow-up 34 (53%) patients were alive. Initial Treatment for Long-term Survivors Forty-four patients (69%) underwent subtotal resection, 7 (11%) had gross total resection, and 13 (20%) had biopsy only. Fifty-four patients (84%) received radiation therapy, 7 did not, and no information was available for 3. Fifty-four patients (84%) received chemotherapy: 31 temozolomide; 9 carmustine; 6 procarbazine, lomustine and vincristine; 5 carmustine and temozolomide in a clinical trial; 1 temozolomide and carboplatin; 1 lomustine and temozolomide; and 1 poly-iclc; 5 did not receive chemotherapy and 5 had no information. Employment Status and Functional Assessment for Long-term Survivors At diagnosis, 53 long-term survivors (83%) were employed full time; 37 were professionals, 10 were white-collar employees, and 6 were blue-collar employees. Eight patients (13%) were unemployed; 3 retired before their brain tumor diagnosis and the remaining 5 had frequent seizures, aphasia, or hemiparesis that prevented them from doing their jobs (Table 2). No information 72 Neuro-Oncology Practice
3 Table 1. Patient characteristics All 5 y OS a 95% CI a Log-rank P Value b LTS c (n ¼ 195) (%) (%) (n ¼ 64) Sex Male 111 (57%) (58%) Female 84 (43%) (42%) Age Median 42 y y Range y Histology AA 167 (86%) (81%) AOA 28 (14%) (19%) Location Frontal lobe 91 (47%) (47%) Temporal lobe 38 (19%) (16%) Parietal lobe 23 (12%) (11%).2 lobes 33 (17%) (20%) Brainstem/occipital 10 (6%) (6%) Extent of resection Biopsy 61 (31%) (20%) Subtotal resection 124 (64%) , (69%) Total resection 10 (5%) d d 7 (11%) Initial KPS (72%) (95%) (21%) , (5%) Unknown 13 (7%) Radiation therapy for AG e Yes 163 (84%) 54 (84%) No 10 (5%) 7 (11%) Unknown 22 (11%) 3 (5%) Chemotherapy for AG e Temozolomide 93 (48%) 31 (48%) Other chemotherapy 58 (29%) 23 (36%) No 17 (9%) 5 (8%) Unknown 27 (14%) 5 (8%) Abbreviations: LTS, long-term survivor ( 5 years); AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; KPS, Karnofsky Performance Score; AG, anaplastic glioma; OS, overall survival; CI, confidence interval. a This is the Kaplan-Meier estimate and corresponding 95% CI for the percentage of patients from the entire cohort (n ¼ 195) who survived 5 or more years in the specified category. b P value is for the comparison of the survival curves of the specified categories. c This column presents the 64 patients who survived 5 or more years and their distribution across the specified categories. d No events before 5 years. e Dates of receipt for radiation therapy and chemotherapy were not available, therefore no time-dependent results could be provided for these 2 variables. on employment status was available for 3 patients. Fifty-six patients (88%) had a normal neurologic exam, 6 (9%) had mild neurologic or cognitive impairment, and 2 (3%) had severe neurologic deficit. Fifty-six patients had information on employment status at both time points and 57 had information on their functional status (Table 3). Only 34 patients (61% of previously employed patients) remained employed full or part-time at 5 or more years from diagnosis; 2 of these patients reported some degree of cognitive problems and 5 had mild neurological impairment. Seven employed patients at the 5-year mark had disease progression but were able to maintain their employment. Only 5 out of 9 patients with pre-existing low-grade glioma were able to maintain their employment. The remainder of the 15 previously employed patients were not able to maintain their employment. One (2%) previously unemployed patient was able to find a job and remained employed 5 years from diagnosis. Six (11%) remained unemployed (Table 3). Among patients with known functional status at baseline and 5 years later, 29 patients (51%) had either maintained or improved to normal function 5 years later. Overall functional impairment, either neurologic or cognitive, was observed in 28 long-term survivors at the 5-year mark (Table 3). Neuro-Oncology Practice 73
4 Discussion This cohort of AG patients had a fairly typical median overall survival of only 2.5 years. However, more than 30% of patients were long-term survivors. Using the classification scheme defined by the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis, class I patients (age, 50 years old, normal mental status) have an estimated median survival of almost 5 years, and most of our long-term survivors fit this profile. Our findings are similar to results of RTOG/ECOG (Eastern Cooperative Oncology Fig. 1. Kaplan Meyer estimates of overall survival (OS) for 195 patients with anaplastic gliomas (AG). Table 2. Employment status and functional assessment at baseline and 5 years in long-term survivors Group) studies reporting long-term survival rates of up to 35% for patients with AA who are treated with radiation therapy only. 14 Interestingly, the RTOG data showed that only 29% of patients treated with radiation therapy plus chemotherapy survived 5 years or more. The natural history of anaplastic oligodendrogliomas and co-deleted AGs is more protracted, with a longer time to disease progression than AG with intact 1p/19q. 15 Co-deleted AG responds better to treatment, and some patients receive less vigorous therapy at diagnosis. 16,17 Thus, we eliminated these patients in an effort to identify a cohort of patients with a similar natural history of disease and typical treatment pattern, which could have affected patients functional status at 5 years. The inclusion of the four AOA long-term survivors whose deletion status was not tested did not affect our findings so we retained them in our analyses. One of the goals of this study was to identify how survivors were affected by the diagnosis and treatment of AG, whether they remained active members of society, and whether they were able to maintain or return to work. The majority of studies on employment status describe problems in cancer survivors of breast or mixed cancer populations who had lost their jobs or quit working within 6 years of diagnosis. 18 Unemployment and early retirement become even more obvious issues for patients with brain tumors who already have localized brain damage and receive treatments directed to the brain lesion. Patients with primary brain tumors may experience greater levels of work limitations than survivors of other types of cancers or healthy adults. 19 Current literature on neurocognitive assessment in glioma patients suggests that patients with brain tumors may Variable Level Long-term Survivors Long-term Survivors with Known Status N % c N % c Employment Status at Baseline Yes No N/A 3 5 Employment Status at 5 y Yes No N/A 8 13 Functional Assessment at Baseline Normal Mild deficit a Severe deficit b Functional Assessment at 5 y Normal Mild deficit a Severe deficit b N/A 7 11 a Defined as: Mild neuro deficit and/or mild cognitive decline. b Defined as: Severe neurologic deficit and/or severe cognitive decline. If a patient had hemiparesis that significantly affected his or her mobility, was wheelchair bound and unable to perform activities of daily living, was significantly aphasic, had a prominent visual deficit, or had severe gait abnormalities, then the patient was considered to have a severe neurologic deficit. Patients with poor memory, poor judgment, and requiring significant assistance to write checks or shop, or patients with frequent, uncontrolled seizures on multiple antiepileptic medications reporting difficulty with memory and concentration were considered to have severe cognitive impairment. c Percentages may not add to 100 due to rounding. 74 Neuro-Oncology Practice
5 Table 3. Change in employment status and functional assessment from baseline to 5 years in long-term survivors Employment Status at Baseline a Employment Status N b ¼ 56 % e at 5 y a A. Employment at Baseline and 5 Y Yes Yes Yes No No Yes 1 2 No No 6 11 Functional Assessment at Baseline c Functional N d ¼ 57 % e Assessment at 5 y c B. Functional Assessment at Baseline and 5 Y Normal Normal Normal Mild Normal Severe Mild Normal 2 4 Mild Mild 1 2 Mild Severe 3 5 Severe Severe 2 4 a Yes is defined as yes or homemaker. No is defined as no or disabled or retired. b Only included patients with known information at both time points. c Where mild is mild neurologic deficit and/or mild cognitive decline. Severe is severe neurologic deficit and/or severe cognitive decline. d Only included patients with known information at both time points. e Percentages may not add to 100 due to rounding. experience a decrease in nonverbal recall and some aspects of executive function related to duration of disease and treatment with radiation and chemotherapy, which could affect their employment status. 20,21 The majority of our long-term survivors had an excellent overall performance status with a median KPS of 100 at diagnosis. However, for this cohort of young adults, only 55% of previously employed patients were employed 5 years or more from diagnosis. Of those employed at diagnosis with known employment status at baseline and 5 years, 34 (61%) retained their employment across a broad range of employment activities, including those who returned to professional activities. We were unable to assess whether patients in all types of industries were able to perform at the same level 5 years later, or received special accommodations or flexible working hours from their employer. Interestingly, 7 patients employed at the 5-year mark, or their caregivers, reported some degree of cognitive problems, especially with short-term memory and neurologic impairment. This raises an important concern as to whether the patients returned to work with limitations or at reduced level. Fifteen (27%) previously employed patients suffered from further disease progression and prominent neurologic deterioration and were not employed 5 years from diagnosis, almost certainly because they were unable to work. Forty-four percent of longterm survivors with known functional status at baseline and at 5 years had functional and neurologic decline, making any employment impossible. Previous studies have focused on quality-of-life and neurocognitive status in cancer survivors. 22 The majority of such studies have been limited by either a small number of patients, short follow-up of 12 months, or patients who predominantly had diagnoses of glioblastoma. 21,23 High quality-of-life scores at diagnosis are associated with improved survival. Progressive memory loss and cognitive decline in long-term survivors with high-grade gliomas have been attributed to chemoradiotherapy. 9,24 However, no prior study has examined the long-term employability of survivors. Patients have also described being overwhelmed with the diagnosis and have experienced depression, fatigue, and emotional distress, with depression being the single-most-important independent predictor of quality of life Evaluations of cognitive domains, quality of life, and neuropsychiatric symptoms are necessary to identify treatable causes of disability in long-term survivors, but the effect of these variables on employment and whether treatment can improve employability are unknown. However, this is a critical issue for these predominantly young adults who often have significant familial financial responsibilities. This study had several limitations, particularly its retrospective nature. KPS and job description at diagnosis were reported in the majority of patients, but these were missing in a significant number of patients 5 years later. For patients who returned to employment, we could not assess whether or not they returned to work in a comparable position. Whether chemotherapy or radiotherapy contributed to work-related problems 5 years from diagnosis was unclear because there were too few patients in each category. We attempted to assess employment status for all survivors; however, data points were missing. No quality-of-life or neuropsychological assessment was done prospectively. Despite those barriers, we found that 55% of long-term survivors were employed 5 years or more from diagnosis. The quality of that employment and the reasons why 45% remained unemployed are pressing issues. The ongoing prospective phase III CAT- NON study for patients with AG has been capturing data on quality of life and cognitive function using Mini-Mental State assessment tools. Developing evaluation tools to understand work-related problems in brain tumor patients is necessary. Unfortunately, the CAT- NON study will not be collecting employment status prospectively. Ideally, a work limitation questionnaire would be completed at diagnosis and prospectively on follow-up examinations to understand those factors associated with a greater likelihood employability. 28,29 A neurocognitive evaluation at diagnosis, at 6 months, at 12 months, and annually thereafter would facilitate development of cognitive and occupational rehabilitation programs for long-term survivors of a brain tumor, similar to those for patients with traumatic brain injury and breast cancer survivors. 30 Our findings expose a critical issue regarding functional capacity for young adults with AG or AOA. While many such patients can have productive lives after diagnosis and treatment, a significant proportion remains functionally compromised and unemployable.thishasseriousimplicationsforsurvivorshipofthis predominantly young adult population and warrants our attention with prospective study. Funding None declared. Acknowledgments We thank Judith Lampron for her editorial assistance. Neuro-Oncology Practice 75
6 Conflict of interest statement. Dr. Pentsova does not have a conflict of interest. Ms. Reiner does not have a conflict of interest. Dr. Panageas does not have a conflict of interest. Dr. DeAngelis does not have a conflict of interest. This paper was presented in part as a poster presentation at the 2010 Annual Meeting of the Society of Neuro-Oncology in Montreal, Canada. References 1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2): CBTRUS. Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in CBTRUS Statistical Report. Hinsdale, Il Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5): Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. JClin Oncol. 2009;27(35): Brandes AA, Nicolardi L, Tosoni A, et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol. 2006;8(3): Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEngl J Med. 2005;352(10): Freyschlag CF, Smolczyk DR, Janzen E, et al. Prolonged administration of temozolomide in adult patients with anaplastic glioma. Anticancer Res. 2011;31(11): Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359(9311): Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol. 1990;28(6): Hottinger AF, Yoon H, DeAngelis LM, Abrey LE. Neurological outcome of long-term glioblastoma survivors. J Neurooncol. 2009;95(3): Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG Int J Radiat Oncol Biol Phys. 1998;40(1): Stupp R, Reni M, Gatta G, Mazza E, Vecht C. Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol. 2007;63(1): Curran WJ Jr., Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85(9): Fischbach AJ, Martz KL, Nelson JS, et al. Long-term survival in treated anaplastic astrocytomas. A report of combined RTOG/ECOG studies. Am J Clin Oncol. 1991;14(5): Lassman AB, Iwamoto FM, Cloughesy TF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011;13(6): Panageas KS, Iwamoto FM, Cloughesy TF, et al. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012;14(6): Abrey LE. The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors. J Neurooncol. 2012;108(2): Mehnert A. Employment and work-related issues in cancer survivors. Crit Rev Oncol Hematol. 2011;77(2): Feuerstein M, Hansen JA, Calvio LC, Johnson L, Ronquillo JG. Work productivity in brain tumor survivors. J Occup Environ Med. 2007; 49(7): Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE. Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol. 2008;86(3): Omuro A, Beal K, Gutin P, et al. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res. 2014;20(19): Corn BW, Wang M, Fox S, et al. Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG J Neurooncol. 2009;95(2): Salcman M, Scholtz H, Kaplan RS, Kulik S. Long-term survival in patients with malignant astrocytoma. Neurosurgery. 1994;34(2): ; discussion Hochberg FH, Slotnick B. Neuropsychologic impairment in astrocytoma survivors. Neurology. 1980;30(2): Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol. 2002; 57(1): Weitzner MA. Psychosocial and neuropsychiatric aspects of patients with primary brain tumors. Cancer Invest. 1999;17(4): ; discussion Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000;18(3): Lerner D, Amick BC 3rd, Rogers WH, Malspeis S, Bungay K, Cynn D. The work limitations questionnaire. Med Care. 2001;39(1): Ladehoff N, Sturm K, Mehnert A. Work-related self-report measures and assessment tools in cancer survivorship: a systematic literature review. Disabil Rehabil. 2013;35(2): Ercoli LM, Petersen L, Hunter AM, et al. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology DOI: /pon Neuro-Oncology Practice
PROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationPRESURGICAL PLANNING. Strongly consider neuropsychological evaluation before functional imaging study Strongly consider functional imaging study
NOTE: Consider Clinical Trials as treatment options for eligible patients. Page 1 of 6 RADIOLOGICAL PRESENTATION PRESURGICAL PLANNING TREATMENT Imaging study suggestive of glioma 1 Left hemisphere speech/motor
More informationSurvival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study
Original Article Research in Oncology June 2017; Vol. 13, No. 1: 18-22. DOI: 10.21608/resoncol.2017.552.1022 Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy:
More informationCarmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma
National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional
More informationScottish Medicines Consortium
Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationPrior to 1993, the only data available in the medical
Neuro-Oncology Prospective clinical trials of intracranial low-grade glioma in adults and children Edward G. Shaw 1 and Jeffrey H. Wisoff Department of Radiation Oncology, Wake Forest University School
More informationZurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 19 CH-857 Zurich http://www.zora.uzh.ch Year: 29 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine
More informationCharacteristics and Outcomes of Elderly Patients With Primary Central Nervous System Lymphoma
Characteristics and Outcomes of Elderly Patients With Primary Central Nervous System Lymphoma The Memorial Sloan-Kettering Cancer Center Experience Douglas E. Ney, MD 1 ; Anne S. Reiner, MPH 2 ; Katherine
More informationElderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard- versus Abbreviated-Course Radiotherapy
Elderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard- versus Abbreviated-Course Radiotherapy Christine N Chang-Halpenny, MD; Jekwon Yeh, MD; Winston W Lien, MD
More informationConcomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
More informationNeuro-Oncology. Martin J. van den Bent. Department of Neuro-oncology/Neurology, Erasmus M.C. Cancer Institute, Rotterdam, Netherlands
Neuro-Oncology Neuro-Oncology 16(12), 1570 1574, 2014 doi:10.1093/neuonc/nou297 Advance Access date 29 October 2014 Practice changing mature results of RTOG study 9802: another positive PCV trial makes
More informationUniversity of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2010 Temozolomide and MGMT forever? Weller, M Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology,
More informationBevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma
Original Article Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma Lin-Bo Cai, Juan Li, Ming-Yao Lai, Chang-Guo Shan, Zong-De Lian, Wei-Ping Hong, Jun-Jie Zhen,
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationGoing Past the Data for Temozolomide. J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D.
Going Past the Data for Temozolomide J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D. Departments of Medicine (JLV), Neurosurgery (JLV) and Pharmacy Practice (LRB)
More informationZurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2009 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine
More informationIncidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide
405 Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide Walter Taal, MD 1 Dieta Brandsma, MD, PhD 1 Hein G. de Bruin, MD, PhD
More informationChemotherapy plus Radiotherapy versus Radiotherapy Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of RTOG 9402
Chemotherapy plus Radiotherapy versus Radiotherapy Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of RTOG 9402 Gregory Cairncross, Meihua Wang, Edward Shaw, Berndt Scheithauer
More informationSurvival Analysis of Glioblastoma Multiforme
DOI:10.22034/APJCP.2018.19.9.2613 RESEARCH ARTICLE Editorial Process: Submission:04/24/2018 Acceptance:08/19/2018 Supapan Witthayanuwat, Montien Pesee*, Chunsri Supaadirek, Narudom Supakalin, Komsan Thamronganantasakul,
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationExamining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.
Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationORIGINAL PAPERS. The Impact of Surgery on the Efficacy of Adjuvant Therapy in Glioblastoma Multiforme
ORIGINAL PAPERS Adv Clin Exp Med 2015, 24, 2, 279 287 DOI: 10.17219/acem/40456 Copyright by Wroclaw Medical University ISSN 1899 5276 Anna Brzozowska 1, 2, A D, Anna Toruń 3, G, Maria Mazurkiewicz1, 2,
More informationStereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13
Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall
More informationManagement of Glioma: The Basics Glioma Update The clinical challenge. Glioma a malignant disease of the CNS
Management of Glioma: The Basics Glioma Update 3 oger Stupp, MD Department of Oncology & Cancer Center University Hospital Zurich, Switzerland (roger.stupp@usz.ch) Bern, 3. August 3 The clinical challenge
More informationResponse to postoperative radiotherapy as a prognostic factor for patients with low-grade gliomas
ONCOLOGY LETTERS 4: 455-460, 2012 Response to postoperative radiotherapy as a prognostic factor for patients with low-grade gliomas MICHAL SPYCH 1,2, LESZEK GOTTWALD 3, EMILIA JESIEŃ LEWANDOWICZ 1,2, SŁAWOMIR
More informationRadioterapia no Tratamento dos Gliomas de Baixo Grau
Radioterapia no Tratamento dos Gliomas de Baixo Grau Dr. Luis Souhami University Montreal - Canada Low Grade Gliomas Relatively rare Heterogeneous, slow growing tumors WHO Classification Grade I Pilocytic
More informationTreatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study
ORIGINAL ARTICLE Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study E.R. Morgan md,* A. Norman md, K. Laing md, and M.D. Seal md ABSTRACT Purpose
More informationTechnology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 NICE 2018. All rights reserved.
More information3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors
research article 213 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors Yilmaz Tezcan and Mehmet Koc Department
More informationNewcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment
Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment Jennifer Wright Neurosurgery SSC Audit Team Jennifer Wright, Rachel Tresman, Cyril Dubois, Surash Surash,
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationEpidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis
Epidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis G. Pesce 1, A. Bordoni, F. Montanaro, R. Renella 3, A. Richetti 1, D. Boscherini 3, S. Mauri 4,
More informationTreatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma: A case series.
School of Medicine Digital Commons@Becker Open Access Publications 2016 Treatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma:
More informationPrimary central nervous system lymphoma (PCNSL)
Neuro-Oncology 14(10):1304 1311, 2012. doi:10.1093/neuonc/nos207 Advance Access publication September 5, 2012 NEURO-ONCOLOGY Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial
More informationBackground. Central nervous system (CNS) tumours. High-grade glioma
25 4. Central nervous system (CNS) tumours Background Two important considerations underpin the choice of treatment fractionation in neurooncology. First, the results of treatment vary widely and, second,
More informationOligodendrogliomas & Oligoastrocytomas
Oligodendrogliomas & Oligoastrocytomas ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely
More informationImaging for suspected glioma
Imaging for suspected glioma 1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless
More informationLow grade glioma: a journey towards a cure
Editorial Page 1 of 5 Low grade glioma: a journey towards a cure Ali K. Choucair SIU School of Medicine, Springfield, IL, USA Correspondence to: Ali K. Choucair, MD. Professor of Neurology, Director of
More informationCNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
More informationBRAIN TUMOURS: SUCCESSES AND CHALLENGES ON THE OTHER SIDE OF THE BLOOD-BRAIN BARRIER
BRAIN TUMOURS: SUCCESSES AND CHALLENGES ON THE OTHER SIDE OF THE BLOOD-BRAIN BARRIER Kathryn M Field and Mark A Rosenthal Department of Medical Oncology, Royal Melbourne Hospital, Victoria, Australia.
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationPrognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases
J Neurosurg 106:575 581, 2007 Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases TAKUMA NOMIYA, M.D., PH.D., 1 KENJI NEMOTO,
More informationConditional survival after a diagnosis of malignant brain tumour in Canada:
ORIGINAL ARTICLE BRAIN CANCER CONDITIONAL SURVIVAL PROBABILITIES: 2000 2008, Yuan et al. Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000 2008 Y. Yuan phd,* J. Ross mph,*
More informationLOW GRADE ASTROCYTOMAS
LOW GRADE ASTROCYTOMAS This article was provided to us by David Schiff, MD, Associate Professor of Neurology, Neurosurgery, and Medicine at University of Virginia, Charlottesville. We appreciate his generous
More informationAn international study under the guidance of the European Organization
2617 COMMENTARY Chemotherapy for Glioblastoma Is Costly Better? Ute Linz, MD, PhD Juelich Research Center, IKP/INB, Juelich, Germany. Address for reprints: Ute Linz, MD, PhD, Forschungszentrum J ulich
More informationTemozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience
Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience *Ehab Abdou and **Mohamed Gaafar *Department of Radiation Oncology, Faculty of Medicine, Al-Azhar University, Cairo,
More informationDose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study
J Neurooncol (2012) 108:195 200 DOI 10.1007/s11060-012-0832-5 CLINICAL STUDY Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study Walter Taal Joyce M. W. Segers-van Rijn
More informationSurvival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.
More informationCitation Pediatrics international (2015), 57.
Title Long-term efficacy of bevacizumab a pediatric glioblastoma. Umeda, Katsutsugu; Shibata, Hirofum Author(s) Hiramatsu, Hidefumi; Arakawa, Yoshi Nishiuchi, Ritsuo; Adachi, Souichi; Ken-Ichiro Citation
More informationNeuro-Oncology Program
Neuro-Oncology Program The goals of the Neuro-oncology Committee are: 1) to improve duration and quality of life of brain tumor patients; 2) to assess disease and treatment-related effects on neurocognitive
More informationUniversity of Alberta. Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers
University of Alberta Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers by Ibrahim Alnaami A thesis submitted to the Faculty of
More informationRetrospective Study of The Corticosteroids Administration in Glioblastoma Patients as A Prognostic Factor in The Disease
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (5), Page 4551-4555 Retrospective Study of The Corticosteroids Administration in Glioblastoma Patients as A Prognostic Factor in The Disease
More informationEfficacy of Treatment for Glioblastoma Multiforme in Elderly Patients (65+): A Retrospective Analysis
Efficacy of Treatment for Glioblastoma Multiforme in Elderly Patients (65+): A Retrospective Analysis Igal Kushnir MD 1 * and Tzahala Tzuk-Shina MD 2 1 Oncology Insitute, Tel Aviv Sourasky Medical Center,
More informationAMERICAN BRAIN TUMOR ASSOCIATION. Oligodendroglioma and Oligoastrocytoma
AMERICAN BRAIN TUMOR ASSOCIATION Oligodendroglioma and Oligoastrocytoma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the
More informationLaboratory data from the 1970s first showed that malignant melanoma
2265 Survival by Radiation Therapy Oncology Group Recursive Partitioning Analysis Class and Treatment Modality in Patients with Brain Metastases from Malignant Melanoma A Retrospective Study Jeffrey C.
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationChemotherapy in malignant brain tumors
Chemotherapy in malignant brain tumors Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH 4031 Basel zimmermannf@uhbs.ch Tumor types Neuro-epithelial tumors - Glioblastoma
More informationRoche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer
Media Release Basel, 1 June 2013 Roche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer Roche (SIX: RO, ROG; OTCQX:
More informationConcurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme
Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme Adam J. Kole, MD, PhD 1 ; Henry S. Park, MD, MPH 1 ; Debra N. Yeboa, MD 1 ; Charles E. Rutter, MD 1 ; Christopher
More informationImpact of Surgery on the Quality of Life in Patients with Primary Brain Tumors (A Review of 170 Patients at a Tertiary Care Hospital)
Impact of Surgery on the Quality of Life in Patients with Primary Brain Tumors (A Review of 170 Patients at a Tertiary Care Hospital) Abstract Z. Babar, S. Khizar, A. Amin, Q. Bhatti, A. Razzaq, I. Khan
More informationdoi: /bjr/
doi: 10.1259/bjr/29022270 Prognostic factors in the consecutive institutional series of glioblastoma multiforme patients who received high-dose particle radiotherapy or conventional radiotherapy Masahide
More informationPROPOSED/DRAFT Local Coverage Determination (LCD): MolDX: Chromosome 1p/19q deletion analysis (DL36483)
moldx: Chromosome 1p/19q deletion analysis (DL36483) Page 1 of 8 PROPOSED/DRAFT Local Coverage Determination (LCD): MolDX: Chromosome 1p/19q deletion analysis (DL36483) Close Section Navigation
More informationPrecision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
More informationNational Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)
National Institute for Health and Clinical Excellence Appendix C Comment 1: the draft scope Single Technology Appraisal (STA) Carmustine implants for the treatment of recurrent glioblastoma multiforme
More informationDurable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment
Durable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationArecent randomized controlled trial (RCT) established
Neuro-Oncology 12(2):190 198, 2010. doi:10.1093/neuonc/nop004 NEURO-ONCOLOGY The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme Rose Lai, Dawn L. Hershman,
More informationJosh is JB s brother and caregiver.
PUT GBM ON PAUSE PUT LIFE ON PLAY Josh is JB s brother and caregiver. JB is an Optune user. OPTUNE + TMZ HAS BEEN PROVEN TO PROVIDE LONG-TERM QUALITY SURVIVAL TO PATIENTS WITH NEWLY DIAGNOSED GBM1,2,*
More informationNeurocognitive Assessment in Patients with Brain Metastases. Martin Klein VU University Medical Center Amsterdam, The Netherlands
Neurocognitive Assessment in Patients with Brain Metastases Martin Klein VU University Medical Center Amsterdam, The Netherlands Treatment Outcomes I Traditional/primary endpoints of efficacy:! Physician
More informationEORTC (RTOG 0834 Endorsed) Opened: July 22, 2009
January 2011 0834-1 EORTC 26053 22054 (RTOG 0834 Endorsed) Protocol Status: Opened: July 22, 2009 Title: Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationIntegrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community
Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community The Harvard community has made this article openly available. Please
More information1. Introduction. Correspondence should be addressed to Christopher M. Lee; Received 9 July 2013; Accepted 27 August 2013
Case Reports in Oncological Medicine Volume 2013, Article ID 431857, 5 pages http://dx.doi.org/10.1155/2013/431857 Case Report Long-Term Survival and Improved Quality of Life following Multiple Repeat
More informationCNAJ12TZRT. Protocol Code. Neuro-Oncology. Tumour Group. Dr. Brian Thiessen. Contact Physician
BC Cancer Protocol Summary for Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Astrocytomas and Oligodendrogliomas with Radiation Protocol Code Tumour Group Contact
More informationSurvival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project
J Neurosurg 99:467 473, 2003 Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project EDWARD R. LAWS, M.D., IAN F. PARNEY, M.D.,
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationAMERICAN BRAIN TUMOR ASSOCIATION. Oligodendroglioma and Oligoastrocytoma
AMERICAN BRAIN TUMOR ASSOCIATION Oligodendroglioma and Oligoastrocytoma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the
More informationDurable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment
Durable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S 2, Carter B 6, Chen
More informationSee the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, An extent of resection threshold for newly diagnosed glioblastomas
See the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, 2011 An extent of resection threshold for newly diagnosed glioblastomas Clinical article Nader Sanai, M.D., 1 Mei-Yin Polley,
More informationZurich Open Repository and Archive. Procarbazine and CCNU as initial treatment in gliomatosis cerebri
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 Procarbazine and CCNU as initial treatment in gliomatosis cerebri Glas, M;
More informationAnatomic locations in high grade glioma
Romanian Neurosurgery (2015) XXIX 3: 271-277 271 Anatomic locations in high grade glioma A. Oslobanu 1, St.I. Florian 2 University of Medicine and Pharmacy, Iuliu Hatieganu Cluj-Napoca 1 Assistant Professor
More informationAdjuvant treatment of high grade gliomas
17 (Supplement 10): x186 x190, 2006 doi:10.1093/annonc/mdl258 Adjuvant treatment of high grade gliomas M. J. van den Bent Department of Neuro-Oncology, Erasmus University Hospital Rotterdam/Rotterdam Cancer
More informationCerebral Lymphoma: Clinical and Radiological Findings in 90 Cases
Arch Iranian Med 27; 1 (2): 194 198 Original Article Cerebral Lymphoma: Clinical and Radiological Findings in 9 Cases Alireza Zali MD *, Sohrab Shahzadi MD*, Alireza Mohammad-Mohammadi MD*, Karim Taherzadeh
More informationA Randomized Phase III study: Comparison between Intravenous and Intraarterial ACNU Administration in Newly Diagnosed Primary Glioblastomas
A Randomized Phase III study: Comparison between Intravenous and Intraarterial ACNU Administration in Newly Diagnosed Primary Glioblastomas F. IMBESI 1, E. MARCHIONI 2, E. BENERICETTI 3, F. ZAPPOLI 4,
More informationClinical Trials for Adult Brain Tumors - the Imaging Perspective
Clinical Trials for Adult Brain Tumors - the Imaging Perspective Whitney B. Pope, M.D., Ph.D. Department of Radiology David Geffen School of Medicine at UCLA August 22, 2015 1 Disclosure of Financial Relationships
More informationStephanie E. Combs Æ Marc Bischof Æ Thomas Welzel Æ Holger Hof Æ Susanne Oertel Æ Jürgen Debus Æ Daniela Schulz-Ertner
J Neurooncol (2008) 89:205 210 DOI 10.1007/s11060-008-9607-4 CLINICAL-PATIENT STUDIES Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT)
More informationMolDX: Chromosome 1p/19q deletion analysis
MolDX: Chromosome 1p/19q deletion analysis CGS Administrators, LLC Jump to Section... Please Note: This is a Proposed LCD. Proposed LCDs are works in progress and not necessarily a reflection of the current
More informationBrain and CNS Cancer. Measurability of Quality Performance Indicators Version 3.0
Brain and CNS Cancer Measurability of Quality Permance Indicators Version 3.0 To be read in conjunction with: Brain and Central Nervous System Cancer Clinical Quality Permance Indicators Brain and Central
More informationCase Presentation: USCAP Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center
Case Presentation: USCAP 2016 Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center Case History 53 year old female with a long standing history of migraines
More informationORE Open Research Exeter
ORE Open Research Exeter TITLE Temozolomide for high grade glioma AUTHORS Hart, MG; Garside, R; Rogers, G; et al. JOURNAL Cochrane Database Of Systematic Reviews DEPOSITED IN ORE 22 October 2013 This version
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Neurologic and Neurosensory Adverse Sequelae in Long-term Survivors of Childhood Brain Tumors: An Update and Expanded Risk Factor Analysis
More informationNeurosurgical Management of Brain Tumours. Nicholas Little Neurosurgeon RNSH
Neurosurgical Management of Brain Tumours Nicholas Little Neurosurgeon RNSH General Most common tumours are metastatic 10x more common than primary Incidence of primary neoplasms is 20 per 100000 per year
More informationRisk Factors for Loss to Follow-up During Active Surveillance of Patients with Stage I Seminoma
Jpn J Clin Oncol 2014;44(4)355 359 doi:10.1093/jjco/hyu001 Advance Access Publication 20 February 2014 Risk Factors for Loss to Follow-up During Active Surveillance of Patients with Stage I Seminoma Tsuyoshi
More informationPediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
More informationTemozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma
Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma Correlation With MGMT Promoter Methylation Status Alba A. Brandes, MD 1 ; Enrico Franceschi, MD 1 ; Alicia Tosoni,
More information